PubMed · 1981 · 40 citations · 0 references
PharmacyBiochemistryToxicologyBiochemical ToxicologyDrug MetabolismMetabolismCytochrome P450 EnzymesCytochrome P450-mediated MetabolismDrug-metabolizing EnzymesHepatic MetabolismMolecular Mechanisms Of ToxicityPulmonary ToxicologyCytochrome EnzymesCytochrome P450 BioactivationCytochrome P450 Enzyme ActivityCytochrome P450 IsoenzymesCytochrome P450 Metabolic PathwaysMetabolic Activation Of AflatoxinsMutagenic EffectivenessMutagenic Mechanisms
The involvement of pulmonary or hepatic cytochrome P-450 monooxygenase enzymes in the activation of the promutagens 2-aminoanthracene, 2-aminofluorene, 2-acetylaminofluorene, and aflatoxin B 1 has been investigated using Salmonella strain TA98. These agents were more readily metabolized to mutagenic products by the 16,000 x g supernatant fraction from lung than from liver despite the low pulmonary cytochrome P-450 content, and more revertants per nanomole of total cytochrome P-450 were consistently obtained with pulmonary than with hepatic microsomal preparations. In reconstituted monooxygenase systems containing the major pulmonary cytochrome P-450 isozymes (P-450 I or P-450 II ), P-450 II was highly effective in the activation of 2-aminoanthracene and 2-aminofluorene and also active with 2-acetylaminofluorene, whereas these substrates were not activated by P-450 I . This difference was confirmed by the results of antibody inhibition studies carried out with pulmonary microsomal preparations. The higher activity of pulmonary preparations relative to hepatic preparations can be accounted for by the relatively high proportion of P-450 II in the lung (approximately 50% total cytochrome P-450 content) as compared with the liver (less than 5%). However, antibody to P-450 II did inhibit the hepatic microsomal activities by 50-70%, indicating that P-450 II may be important in the activation of these agents in both tissues even though it is a minor component in the liver. Aflatoxin B 1 was activated only by P-450 I in reconstituted monooxygenase systems, although the antibody inhibition studies indicated activation by both P-450 I and P-450 II in pulmonary microsomal preparations.